loading
Precedente Chiudi:
$67.59
Aprire:
$67.72
Volume 24 ore:
54,313
Relative Volume:
0.04
Capitalizzazione di mercato:
$7.26B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
54.30
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-3.40%
1M Prestazione:
-7.49%
6M Prestazione:
+14.10%
1 anno Prestazione:
+96.29%
Intervallo 1D:
Value
$67.69
$68.67
Intervallo di 1 settimana:
Value
$67.44
$71.57
Portata 52W:
Value
$32.33
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Nome
Corcept Therapeutics Inc
Name
Telefono
650.688.8803
Name
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Dipendente
500
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-17
Name
Ultimi documenti SEC
Name
CORT's Discussions on Twitter

Confronta CORT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
68.44 7.25B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.84 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.55 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
327.43 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.46 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.49 31.91B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-11-06 Aggiornamento Truist Hold → Buy
2023-04-11 Iniziato SVB Securities Market Perform
2023-04-04 Iniziato Piper Sandler Overweight
2023-02-15 Downgrade Jefferies Buy → Hold
2022-08-01 Downgrade Truist Buy → Hold
2022-07-27 Aggiornamento Jefferies Hold → Buy
2022-06-27 Ripresa Canaccord Genuity Buy
2022-02-02 Iniziato Canaccord Genuity Buy
2022-01-28 Iniziato Truist Buy
2020-08-05 Downgrade Jefferies Buy → Hold
2019-09-24 Iniziato Jefferies Buy
2019-09-06 Iniziato H.C. Wainwright Buy
2019-02-04 Downgrade B. Riley FBR Buy → Neutral
2018-08-10 Reiterato Stifel Hold
2018-05-31 Downgrade Stifel Buy → Hold
2018-03-09 Iniziato B. Riley FBR, Inc. Buy
2017-08-31 Iniziato Stifel Buy
2017-02-02 Iniziato Ladenburg Thalmann Buy
2015-04-21 Iniziato FBR Capital Outperform
2014-01-13 Downgrade Stifel Buy → Hold
2013-08-09 Downgrade Janney Buy → Neutral
2013-08-09 Downgrade Ladenburg Thalmann Buy → Neutral
2012-02-21 Reiterato JMP Securities Mkt Outperform
2010-01-06 Aggiornamento Ladenburg Thalmann Neutral → Buy
2008-07-17 Iniziato Rodman & Renshaw Mkt Outperform
2007-06-21 Aggiornamento Punk, Ziegel & Co Mkt Perform → Accumulate
Mostra tutto

Corcept Therapeutics Inc Borsa (CORT) Ultime notizie

pulisher
02:19 AM

What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional

02:19 AM
pulisher
01:29 AM

Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com

01:29 AM
pulisher
Jul 24, 2025

Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo Finance

Jul 24, 2025
pulisher
Jul 24, 2025

Should I buy Corcept Therapeutics Incorporated stock before earningsTriple-digit returns - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Corcept Therapeutics Incorporated stock priceFree Predictions - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire

Jul 24, 2025
pulisher
Jul 23, 2025

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance

Jul 23, 2025
pulisher
Jul 22, 2025

Is Corcept Therapeutics Incorporated a good long term investmentFree Wealth Management Insights - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

Jul 21, 2025
pulisher
Jul 20, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st

Jul 20, 2025
pulisher
Jul 18, 2025

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - TradingView

Jul 18, 2025
pulisher
Jul 17, 2025

FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News

Jul 17, 2025
pulisher
Jul 16, 2025

M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals

Jul 15, 2025
pulisher
Jul 14, 2025

Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Submits New Drug Application to FDA - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jul 14, 2025
pulisher
Jul 11, 2025

Corcept Therapeutics’ Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 06, 2025

Corcept Therapeutics: A New Standard of Care in Ovarian Cancer Emerges - AInvest

Jul 06, 2025
pulisher
Jul 06, 2025

Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial - MSN

Jul 06, 2025
pulisher
Jul 05, 2025

13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jul 05, 2025
pulisher
Jul 04, 2025

A New Dawn in Diabetes Treatment: Corcept Therapeutics' Korlym and the Untapped $2.8 Billion Opportunity - AInvest

Jul 04, 2025
pulisher
Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares By Investing.com - Investing.com Canada

Jul 03, 2025
pulisher
Jul 03, 2025

Corcept therapeutics officer Guyer sells $7350 in shares - Investing.com

Jul 03, 2025
pulisher
Jul 02, 2025

Adrenocortical Carcinoma Pipeline Therapeutics Gets a Boost With 20+ Active Pharma Players | DelveInsight - The Globe and Mail

Jul 02, 2025
pulisher
Jul 02, 2025

10 Best NASDAQ Growth Stocks to Buy for the Next 3 Years - Insider Monkey

Jul 02, 2025
pulisher
Jun 30, 2025

Corcept Therapeutics (NasdaqCM:CORT) Dropped From Russell 2000 and Growth Index - Yahoo Finance

Jun 30, 2025
pulisher
Jun 29, 2025

Corcept Therapeutics Incorporated(NasdaqCM: CORT) added to Russell Midcap Index - MarketScreener

Jun 29, 2025
pulisher
Jun 24, 2025

Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint - Yahoo Finance

Jun 24, 2025
pulisher
Jun 23, 2025

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85 - Business Wire

Jun 23, 2025
pulisher
Jun 19, 2025

Insider Decision: Gary Charles Robb Offloads $225K Worth Of Corcept Therapeutics Stock - Nasdaq

Jun 19, 2025
pulisher
Jun 16, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada

Jun 16, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com UK

Jun 13, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia

Jun 13, 2025

Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Corcept Therapeutics Inc Azioni (CORT) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Maduck Sean
See Remarks
Jul 18 '25
Option Exercise
5.05
473
2,389
18,178
Maduck Sean
See Remarks
Jul 17 '25
Sale
73.48
4,315
317,054
17,705
Maduck Sean
See Remarks
Jul 18 '25
Sale
73.44
473
34,737
17,705
BELANOFF JOSEPH K
Chief Executive Officer
Jul 17 '25
Sale
73.69
615
45,318
2,901,370
Lyon Joseph Douglas
See Remarks
Jul 17 '25
Option Exercise
13.56
3,877
52,572
13,943
Lyon Joseph Douglas
See Remarks
Jul 18 '25
Option Exercise
13.56
200
2,712
10,266
Lyon Joseph Douglas
See Remarks
Jul 17 '25
Sale
73.48
3,877
284,864
10,066
Lyon Joseph Douglas
See Remarks
Jul 18 '25
Sale
73.40
200
14,680
10,066
Guyer William
Chief Development Officer
Jul 17 '25
Option Exercise
21.65
4,379
94,805
9,866
Guyer William
Chief Development Officer
Jul 18 '25
Option Exercise
21.65
500
10,825
5,987
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Capitalizzazione:     |  Volume (24 ore):